We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click ...

StockNews.com cut shares of Elevance Health (NYSE:ELV – Free Report) from a buy rating to a hold rating in a research note ...

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a ...

In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price ...

Wells Fargo & Company reduced their target price on shares of Elevance Health from $593.00 to $495.00 and set an “overweight” rating on the stock in a report on Monday, November 4th.

Despite a 29% drop in Elevance Health's stock, I maintain a strong buy rating due to a DCF price target of $549.60, indicating 43% upside. ELV's shift towards managed care, with strong industry ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

An analyst from Truist Securities persists with their Buy rating on Elevance Health, maintaining a target price of $480. Options are a riskier asset compared to just trading the stock, but they ...